Theriva Biologics reveals positive VCN-01 study results
The candidate is a stroma-degrading oncolytic adenovirus for the treatment of pancreatic cancer
Read Moreby John Pinching | Aug 3, 2023 | News | 0
The candidate is a stroma-degrading oncolytic adenovirus for the treatment of pancreatic cancer
Read Moreby John Pinching | Jul 27, 2023 | News | 0
OCTP aims to demonstrate the lead candidate’s safety, tolerability and pharmacokinetic profile
Read Moreby John Pinching | Sep 28, 2022 | News | 0
Results show reduction of clinical decline in global study of people with Alzheimer’s Disease
Read Moreby John Pinching | Aug 4, 2022 | News | 0
Candidate exhibits a novel mechanism of action and differs considerably from previously approved drugs
Read Moreby John Pinching | Apr 22, 2022 | News | 0
Infertility is estimated to affect one in seven couples across the UK and can have a profound effect on mental health
Read Moreby Anna Smith | Mar 2, 2020 | News | 0
Last year it was revealed that a “record number” of children are being hospitalised for eating disorders.
Read Moreby Anna Smith | Jan 17, 2020 | News | 0
The new study included data from low- and middle-income countries, bringing the estimated total from 5.3 million deaths to 11 million.
Read Moreby Selina McKee | Sep 18, 2018 | News | 0
Researchers are calling for 40,000 people with depression or anxiety in England to join an online study hoping to explore any genetic links to these conditions.
Read Moreby Selina McKee | Feb 22, 2018 | News | 0
A large-scale review of the most common antidepressants has found them all to be superior to placebo in treating major depression, potentially laying to rest questions over their effectiveness.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
